Bio-Rad Labs (BIO) Tops Q1 EPS by 55c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Bio-Rad Reports First Quarter 2019 Financial Results
May 8, 2019 4:15 PM EDTHERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2019.
First-quarter 2019 net sales were $554.0 million, an increase of 0.4 percent compared to $551.5 million reported for the first quarter of 2018. On a currency-neutral basis, quarterly sales increased 4.0 percent compared to the same period in 2018. First-quarter gross margin was 56.3 percent compared to 54.8 percent during the first quarter in 2018.
Life Science segment net sales for the first quarter were $215.7 million, an increase of 9.1 percent compared to the same... More
